<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996228</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0002</org_study_id>
    <nct_id>NCT01996228</nct_id>
  </id_info>
  <brief_title>Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy</brief_title>
  <official_title>Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianhe Stem Cell Biotechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianhe Stem Cell Biotechnologies Inc.</source>
  <brief_summary>
    <textblock>
      Type 1 diabetes (T1D) is an autoimmune disease that usually occurs in children and reduces
      their pancreatic islet beta cells and thereby limits insulin production. Millions of
      individuals worldwide have T1D, and the number of children with diagnosed or undiagnosed T1D
      is increasing annually. Insulin supplementation is not a cure. It does not halt the
      persistent autoimmune response, nor can it reliably prevent devastating complications such as
      neuronal and cardiovascular diseases, blindness, and kidney failure. A true cure has proven
      elusive despite intensive research pressure over the past 25 years. Notably, Dr.Zhao and his
      team have successfully developed a groundbreaking technology Stem Cell Educator therapy (Zhao
      Y, et al.BMC Medicine 2011, 2012). To date, clinical trials in adult patients have
      demonstrated the safety and efficacy of Stem Cell Educator therapy for the treatment of T1D
      and other autoimmune-associated diseases. Here, the investigators will evaluate the safety
      and efficacy of Stem Cell Educator therapy in children with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autoimmune control</measure>
    <time_frame>90 days post treatment</time_frame>
    <description>Before treatment, test autoimmune-related markers as baseline; After treatment for 90 days, repeat testing autoimmune-related markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic control</measure>
    <time_frame>3-24 months post treatment</time_frame>
    <description>Before treatment, test for C-peptide levels and HbA1C as baseline; After treatment, test C-peptide levels and HbA1C on the 3rd month.
Analysis of islet beta cell function
Test for C-peptide levels on every 6 month;
Full evaluation of islet beta cell function after two years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cord Blood-derived multipotent stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stem Cell Educator</intervention_name>
    <arm_group_label>Cord Blood-derived multipotent stem cells</arm_group_label>
    <other_name>Procedure: Apharesis and Stem Cell Educator Therapy</other_name>
    <other_name>Biological: Cord blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. T1D patients are screened for enrollment in the study if both clinical signs and
             laboratory tests meet the diagnosis standards of American Diabetes Association.

             2. Children from 3 through 18 years old and body weight &gt; 15 kg.

             3. Presence of at least one autoantibody to the pancreatic islet β cells (IA-2, GAD,
             ICA, ZnT8, or IAA).

             4. Written informed consent from the child and child's parents or legal
             representative.

        Exclusion Criteria:

          -  1. Any clinically significant diseases in liver, kidney, and heart.

             2. Additional exclusion criteria include no immunosuppressive medication, no viral
             diseases or diseases associated with immunodeficiency

             3. Significantly abnormal hematology results at screening.

             4. Presence of any infection diseases or inflammation conditions, including active
             skin infections, flu, fever, upper or lower respiratory track infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Zhao, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianhe Stem Cell Biotechnologies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiguang Zhou, Md,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Zhao, MD, PhD</last_name>
    <phone>001 630 723 1968</phone>
    <email>zhao@tianhecell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Li, MD, PhD</last_name>
      <email>info.T1D@tianhecell.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.tianhecell.com</url>
    <description>Tianhe Stem Cell Biotechnologies</description>
  </link>
  <reference>
    <citation>Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T. Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3.</citation>
    <PMID>22233865</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, Yin Z, Chen Y, Zhang Y, Wang S, Shen J, Thaker H, Jain S, Li Y, Diao Y, Chen Y, Sun X, Fisk MB, Li H. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med. 2013 Jul 9;11:160. doi: 10.1186/1741-7015-11-160.</citation>
    <PMID>23837842</PMID>
  </reference>
  <reference>
    <citation>Zhao Y. Stem cell educator therapy and induction of immune balance. Curr Diab Rep. 2012 Oct;12(5):517-23. doi: 10.1007/s11892-012-0308-1. Review.</citation>
    <PMID>22833322</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Mazzone T. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmun Rev. 2010 Dec;10(2):103-7. doi: 10.1016/j.autrev.2010.08.011. Epub 2010 Aug 20. Review.</citation>
    <PMID>20728583</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianhe Stem Cell Biotechnologies Inc.</investigator_affiliation>
    <investigator_full_name>Yong Zhao, MD, PhD</investigator_full_name>
    <investigator_title>Associate Scientist</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>autoimmune</keyword>
  <keyword>cord blood stem cell</keyword>
  <keyword>stem cell educator</keyword>
  <keyword>immune modulation</keyword>
  <keyword>children</keyword>
  <keyword>Control autoimmunity</keyword>
  <keyword>stimulate the regeneration of islet beta cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

